Know what’s really happening at
Syntax Bio before you sign on.
- On the roadmap
- Cell Therapy
- Regenerative Medicine
- Biotechnology
Syntax Bio uses its Cellgorithm platform to program stem cell differentiation via CRISPR-based genetic programming, aiming to accelerate and reduce the cost of cell-derived therapies. With backing from strategic investors including Astellas Venture Management, Illumina Ventures, and Mayo Clinic, the Chicago-based startup is positioning itself at the intersection of synthetic biology and regenerative medicine.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
Syntax Bio
- Series A raised (June 2026)
- $14.4M
- Total funding to date
- ~$15.3M
- Year founded
- 2021
- Employee count
- 13
- Funding rounds completed
- 3
- Headquarters
- Chicago, Illinois, United States
- Estimated revenue
- $1.3M
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Cell Therapy landscape
- Cell Therapy growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- Syntax Bio TAM
- Cell Therapy market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does Syntax Bio do
- Syntax Bio product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- Syntax Bio customers
- who uses Syntax Bio
- Syntax Bio ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- Syntax Bio competitors
- Syntax Bio alternatives
- who competes with Syntax Bio
- Syntax Bio win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- Syntax Bio reviews
- Syntax Bio NRR
- Syntax Bio churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- Syntax Bio investment thesis
- Syntax Bio moat
- bull case bear case
- Syntax Bio risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- Syntax Bio ARR
- Syntax Bio revenue
- Syntax Bio valuation
- unit economics
Team and culture
Founders, leadership, and org.
- Syntax Bio founders
- Syntax Bio CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Analysis based on structured company profile data and public funding records as of July 2026.